

**SARC Semiannual Meeting Agenda**  
**Friday, June 2, 2017**

8:00	Opening Remarks	
	Mac Tichenor, SARC Board Chair	
8:05	Chawla Rosenfeld Developmental Therapeutics Symposium	
	Introduction	Robert Maki, MD, PhD David Kirsch, MD, PhD
	Overview of TCGA	Elizabeth Demicco, MD, PhD
	Immune signatures	Ian Davis, MD, PhD
	Q & A	
	Genomic Characterization of Pediatric Tumors	Timothy Triche, MD, PhD
	Molecular Tumor Boards: What's next for sarcoma genomics	Andrew Brohl, MD
	Demonstration of SARC Genomic Portal	Corrie Painter, PhD Lisa McFerrin, PhD
	<i>Discussion/Q&amp;A</i>	Panel
10:00	Break	
10:15	Resources for Investigators: SARC Unified Data System	
	Biospecimen Repository	David Kirsch, MD, PhD
	Clinical Data Repository	Karla Ballman, PhD
	Imaging Repository	Fran Laurie, BS
	Demonstration Project: Grant Opportunity	Robert Maki, MD, PhD
10:50	Career Development Program	
	2017 Award Announcement	Elizabeth Lawlor, MD, PhD
10:55	SARC Sarcoma SPORE	
	Update on Competitive Renewal	Laurence Baker, DO
11:00	SARC Clinical Trials	
	Long Term Follow-up Protocol	Scott Okuno, MD
	SARC024: Phase 2 trial of regorafenib in refractory selected subtypes of sarcomas	Robert Maki, MD, PhD Richard Riedel, MD Steven Attia, DO Christopher Ryan, MD/Lara Davis, MD Leo Mascarenhas, MD
	SARC025-SPORE03: Phase 1 trial of niraparib and temozolomide or irinotecan in incurable Ewing sarcoma.	Rashmi Chugh, MD Sandra Strauss, MD, PhD
	SARC028: Phase 2 trial of the anti-PD1 antibody pembrolizumab (MK-3475) in patients with advanced sarcomas	Melissa Burgess, MD Hussein Tawbi, MD, PhD
	SU2C-SARC032-SPORE05: Phase 2 randomized trial of anti-PD1 antibody neoadjuvant/adjuvant pembrolizumab (MK-3475) in patients newly diagnosed extremity UPS or Liposarcoma given with neoadjuvant RT and surgery	David Kirsch, MD, PhD Richard Riedel, MD
	SARC033-ETCTN NCI Protocol #10015: Phase 2 trial of trametinib in unresectable or metastatic epithelioid hemangioendothelioma	Scott Schuetze, MD, PhD
12:00	Closing Remarks - Adjourn	